newsfilter
← Latest News
ClinicalTrials.gov·

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis - NCT04992546

Adverse events (AEs) and serious AEs, Assessment of local cutaneous tolerability, Plasma PRN473 concentrations